It’s no wonder Nurix was a billion-dollar company even before that announcement. You see, they are playing with multiple cards:
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Google partial translation:
In addition to the collaboration with Roche, Sanofi continues to develop the STAT6 degrader, NX-3911, in IND-enabling studies. Following clinical proof of concept, Nurix has the right to participate in a 50/50 profit share and co-development in the United States. Gilead continues to develop the IRAK-4 degrader, GS-6791, in an ongoing first-in-human Phase 1 study in healthy volunteers. Following Phase 1, Nurix has the right to participate in a 50/50 profit share and co-development in the United States, subject to certain limitations. Nurix and Pfizer continue to advance multiple preclinical Degrader-Antibody Conjugate (DAC) programs. In the second quarter of 2026, Nurix received a $2 million milestone payment from Sanofi.
Finnish companies (Herantis, Faron) could learn a thing or two from that. Aiforia seems to be giving it a try.